Juno Therapeutics' (JUNO) JCAR015 Clinical Hold Sends Ripples Throughout Space
Tweet
Share
E-mail
Get Alerts JUNO Hot Sheet
Join SI Premium – FREE
News that the FDA placed a clinic hold on Juno Therapeutics' (NASDAQ: JUNO) JCAR015 after two patient deaths appears to have sent ripples throughout biotech space. Post-market weakness was seen beyond just Juno's peers group and appears to be impacting iShares Nasdaq Biotechnology (NASDAQ: IBB), an ETF that tracks the Nasdaq Biotech index.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Is China exporting deflation? BoFA weighs in
- Meta earnings, IBM to acquire HashiCorp, U.S. GDP ahead - what's moving markets
Create E-mail Alert Related Categories
ETFs, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
